Sensorion announces that its partnership with the Pasteur Institute for the acceleration of gene therapy programs targeting hearing disorders has been extended for a period of five years
• The extension of the framework agreement highlights the fruitful collaboration between Sensorion and the Pasteur Institute, involving the Hearing Institute, a research center of the Pasteur Institute, focused on the development of gene therapy drug candidates
Two gene therapy development programs are currently being conducted under this agreement, namely SENS-501 (OTOF-GT) and GJB2-GT. Sensorion submitted a clinical trial application in July 2023 for SENS-501 to initiate a Phase 1/2 clinical trial in the United Kingdom (UK) and European Union (EU)